Is there a relationship between intraoperative hemodynamic instability and calcineurin inhibitor-related toxicity, early after liver transplantation? A single-center observational study

Transplant Proc. 2014 Jul-Aug;46(6):1789-93. doi: 10.1016/j.transproceed.2014.05.018.

Abstract

This study evaluated the relationship between intraoperative hemodynamic instability (IOHI) and the development of calcineurin inhibitor (CNI) toxicity in the early postoperative period after liver transplantation (LT). Eighty-two patients were enrolled during a 1-year period and a 3-month follow-up. IOHI, requiring continuous infusion of vasopressors, was observed in 31 patients (38%, group 1; control group 2, n = 51). Acute kidney injury (AKI) developed in 28 patients (52% in group 1 vs 24% in group 2, P = .02), and CNI-related neurotoxicity (CNI-NT) in 26 (48% in group 1 vs 22% in group 2, P = .03). Group 1 patients received mainly deceased donor grafts (87% vs 57% in group 2, P < .001). An independent association between IOHI and CNI-NT (P = .029) and AKI (P = .016) was observed. The receiver-operator characteristic curve revealed an area under the curve of 0.63 for IHI (sensitivity 56%; specificity 75%) and 0.65 for AKI (sensitivity 56%; specificity 70.2%). In conclusion, patients undergoing LT with IOHI may be more prone to developing CNI-NT and AKI in the early postoperative period.

Publication types

  • Observational Study

MeSH terms

  • Acute Kidney Injury / chemically induced
  • Adult
  • Calcineurin Inhibitors / adverse effects*
  • Female
  • Follow-Up Studies
  • Hemodynamics
  • Humans
  • Hypertension / chemically induced
  • Hypotension* / drug therapy
  • Hypotension* / etiology
  • Intraoperative Complications* / drug therapy
  • Intraoperative Complications* / etiology
  • Liver Transplantation*
  • Male
  • Middle Aged
  • Neurotoxicity Syndromes / etiology
  • Postoperative Complications / chemically induced*
  • Prospective Studies
  • ROC Curve
  • Treatment Outcome
  • Vasoconstrictor Agents / therapeutic use

Substances

  • Calcineurin Inhibitors
  • Vasoconstrictor Agents